ArticleCardiovascular diabetology2024
Revisiting an old relationship: the causal associations of the ApoB/ApoA1 ratio with cardiometabolic diseases and relative risk factors-a mendelian randomization analysis.
Article in Cardiovascular diabetology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Apolipoprotein B/A1 Ratio Improves Discrimination of Severe Atherosclerosis Beyond Conventional Lipid Markers in High-Risk Statin-Naive Patients.Journal of clinical medicine · 2026Article
- Relationship between sortilin with ApoB/ApoA ratio in military personnel with arterial hypertension.Scientific reports · 2026Article
- A Novel ApoB/ApoA1 Ratio-Integrated Nomogram to Predict Cardiogenic Shock After Acute Myocardial Infarction.Reviews in cardiovascular medicine · 2026Article
- Multivariate Regression With Dependence Structures: Evaluating Associations Between Plasma Metabolomics and Alcohol Intake in Older Adults.Statistics in medicine · 2026Article
- Apolipoprotein B/A1 Ratio for Predicting Major Adverse Cardiovascular Events in Coronary Artery Disease: Development and Validation of a Nomogram.International journal of general medicine · 2026Article
- Clinical utility of lipoprotein(a) and the ApoB/ApoA-I ratio in the risk assessment of acute coronary syndrome: from single biomarkers to integrated risk stratification.Frontiers in cardiovascular medicine · 2026Review
- Dynamic evaluation of serum atherogenic factors as a predictor of QT interval prolongation in patients with type 2 diabetes mellitus.American journal of translational research · 2026Article
- Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers.Frontiers in cardiovascular medicine · 2026Review
- Association between the ApoB/ApoA1 ratio and both the severity and mortality of metabolic dysfunction-associated fatty liver disease.BMC gastroenterology · 2025Article
- Transcriptome remodelling and changes in growth and cardiometabolic phenotype result following Grb10a knockdown in the early life of the zebrafish.Cellular and molecular life sciences : CMLS · 2025Article
- Liraglutide Reduces Liver Steatosis and Improves Metabolic Indices in Obese Patients Without Diabetes: A 3-Month Prospective Study.International journal of molecular sciences · 2025Article
- Gallstones in the Era of Metabolic Syndrome: Pathophysiology, Risk Prediction, and Management.Cureus · 2025Review
- A combined observational and Mendelian randomization investigation reveals NMR-measured analytes to be risk factors of major cardiovascular diseases.Scientific reports · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been confirmed that the ApoB/ApoA1 ratio is closely associated with the incidence of cardiometabolic diseases (CMD). However, due to uncontrolled confounding factors in observational studies, the causal relationship of this association remains unclear.
methodsIn this study, we extracted the ApoB/ApoA1 ratio and data on CMD and its associated risk factors from the largest European Genome-Wide Association Study. The purpose was to conduct Mendelian Randomization (MR) analysis. The causal relationship between the ApoB/ApoA1 ratio and CMD was evaluated using both univariable and multivariable MR analyses. Furthermore, bidirectional MR analysis was performed to estimate the causal relationship between the ApoB/ApoA1 ratio and risk factors for CMD. The final verification confirmed whether the ApoB/ApoA1 ratio exhibits a mediating effect in CMD and related risk factors.
resultsIn terms of CMD, a noteworthy correlation was observed between the increase in the ApoB/ApoA1 ratio and various CMD, including ischemic heart disease, major adverse cardiovascular events, aortic aneurysm, cerebral ischemic disease and so on (all P
conclusionsThis MR study provides evidence supporting the significant causal relationship between the ApoB/ApoA1 ratio and CMD and its risk factors. Moreover, it demonstrates the mediating effect of the ApoB/ApoA1 ratio in CMD and its risk factors. These findings suggest that the ApoB/ApoA1 ratio may serve as a potential indicator for identifying the risk of developing CMD in participants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.